Patent · US Expired

Anti-C5 monoclonal antibodies

US6534058B2 · kind B2 · utility

35Cited by

8References

8Claims

0Family size

Assignee

TANOX, INC. · US

Inventors

Michael S. C. Fung · Houston, US
Bill N. C. Sun · Bellaire, US
Cecily R. Y. Sun · Bellaire, US

Key dates

Filing date	Oct 4, 2001
Grant date	Mar 18, 2003
Priority date	—
Expiry date	Oct 4, 2021

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/505
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to C5 inhibitors, which inhibit type II endothelial cell activation, wherein the inhibition is manifested by the suppression of E-selectin. These inhibitors are useful in treatment of delayed xenograft rejection or acute vascular rejection. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. Examples of monoclonal antibodies, which bind to and inhibit C5, were generated and are designated MAb 137-76 and MAb 137-30.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.